TissueTech Secures $55.3M in Equity Financing to Advance Cryopreservation of Umbilical Cord and Amniotic Membrane Tissues

VCBeat (WeChat ID: vcbeat) has learned that a recent filing with the U.S. Securities and Exchange Commission (SEC) reveals that regenerative medicine company TissueTech has completed a $55.3 million equity financing round. This round involved three unnamed investors. The company aims to raise an additional $27 million, which would bring the total amount raised in this round to $82.3 million.

TissueTech, founded in 1997 and headquartered in Florida, USA, is a leader in the field of regenerative medicine in the United States. It is dedicated to promoting wound healing, treating ocular surface diseases, and addressing musculoskeletal disorders by leveraging the innate regenerative properties of human umbilical cord and amniotic membrane tissues. The company’s technologies and products have secured more than 30 patents in the United States.

Crunchbase shows that since its establishment, TissueTech has completed a total of four rounds of financing. In August 2013, the company completed a $10 million Series A funding round invested by Ballast Point Ventures and River Cities Capital Funds; in June 2015, the company secured another $15 million investment from River Cities Capital Funds.

TissueTech is the first company in the United States to offer cryopreserved amniotic membrane and umbilical cord products to the market, with its groundbreaking innovations in regenerative medicine capable of treating a variety of diseases. Regenerative medicine is understood to restore injured or diseased bodies to a healthy state. In the 1970s, scientists discovered that placental tissues (particularly umbilical cord and amniotic membrane tissues) possess inherent healing properties, which can be preserved and transplanted into other environments to promote human tissue regeneration. With over 30 years of funding from the National Institutes of Health (NIH), TissueTech developed CryoTek technology to preserve the intrinsic properties of umbilical cord and amniotic membrane tissues.

CryoTek technology is a foundational cryopreservation technique that utilizes proprietary tissue processing methods to preserve the biological structure of native placental tissue, thereby retaining its anti-inflammatory, anti-scarring, and anti-angiogenic properties. Notably, CryoTek technology is the only method proven to effectively preserve the Heavy Chain-Hyaluronic Acid/Pentraxin 3 (HC-HA/PTX3) complex, which promotes regenerative healing in human tissues. The clinical benefits of CryoTek technology have been substantiated in over 300 publications.

TissueTech owns two subsidiaries, one of which is Bio-Tissue. Established in 2003, Bio-Tissue is a leader in ocular surface therapy and ocular hygiene solutions in the United States. It is dedicated to developing regenerative biologic therapies to help eye care professionals treat ocular conditions such as keratitis, recurrent corneal erosion, conjunctivochalasis, pterygium, and dry eye disease. The company’s products utilize CryoTek technology to ensure that ocular tissues retain their full bioactivity, thereby reducing inflammation, promoting healing, and minimizing corneal scarring.

Amniox Medical, another subsidiary of TissueTech, was established in 2011 as a provider of human umbilical cord and amniotic tissue matrices, with a focus on the wound care market. Its Neox wound allograft, developed based on CryoTek technology, can be used to promote wound healing and treat conditions such as skin ulcers and defects, as well as chronic diabetic foot ulcers.

(Compiled by Jiao Yanli)